HLA
CLSD

Hamilton Lane Advisors’s Clearside Biomedical CLSD Stock Holding History

Hamilton Lane Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,357
Closed -$73K – 65
2022
Q4 		$73K Buy
+4,357
New +$78.5K 0.03% 64

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Hamilton Lane Advisors's CLSD Position: Q1 2023 in Review

Hamilton Lane Advisors sold out of Clearside Biomedical (CLSD) in Q1 2023, closing a stake of 4,357 shares — an estimated $73K sold.

Hamilton Lane Advisors first reported a position in CLSD in Q4 2022 and held it in 1 quarter. The position peaked at $73K in Q4 2022. 50 funds tracked by Wall St. Rank hold CLSD as of Q1 2023.

  • Hamilton Lane Advisors reported no remaining Clearside Biomedical position as of Q1 2023 after selling out during the quarter.
  • Hamilton Lane Advisors sold 4,357 Clearside Biomedical shares in Q1 2023, an estimated $73K.
  • Hamilton Lane Advisors first reported a position in Clearside Biomedical in Q4 2022 and held it in 1 quarter.
  • Hamilton Lane Advisors's Clearside Biomedical position peaked at $73K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2023.

Based on Hamilton Lane Advisors's 13F filing for Q1 2023, filed 2 May 2023.